Acasti Pharma Inc. (ACST)
NASDAQ: ACST · IEX Real-Time Price · USD
2.89
-0.02 (-0.69%)
At close: Dec 29, 2023, 4:00 PM
2.85
-0.04 (-1.38%)
After-hours: Dec 29, 2023, 6:28 PM EST
Company Description
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was incorporated in 2002 and is headquartered in Laval, Canada.
Acasti Pharma Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 609-649-9272 |
| Website | acastipharma.com |
Stock Details
| Ticker Symbol | ACST |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| CUSIP Number | 00430K402 |
| ISIN Number | CA00430K8656 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Janelle D'Alvise | President, Chief Executive Officer, Corporate Secretary and Director |
| Dr. Pierre Lemieux M.D., Ph.D. | Co-Founder, Chief Operating Officer and Chief Scientific Officer |
| Brian D. Ford CPA, CA | Chief Financial Officer |
| Dr. George Kottayil | Chief Operating Officer of US |
| Prashant Kohli | Chief Commercial Officer |
| Dr. Yves Lachance Ph.D. | Vice President of Quality and Compliance |
| Christine Pelletier | Senior Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 15, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Oct 23, 2023 | 8-K | Current Report |
| Oct 16, 2023 | EFFECT | Notice of Effectiveness |
| Oct 16, 2023 | 424B3 | Prospectus |
| Oct 11, 2023 | 8-K | Current Report |
| Oct 10, 2023 | D | Notice of Exempt Offering of Securities |
| Oct 6, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 26, 2023 | 8-K | Current Report |